Current pharmacological therapy for rheumatoid arthritis, factors for its effectiveness and associated complications: systematic review
DOI:
https://doi.org/10.56294/ri202476Keywords:
Rheumatoid Arthritis, Clinical Effectiveness, Methotrexate, Biological Therapies, ImmunosuppressionAbstract
Rheumatoid arthritis (RA) is a chronic, autoimmune, and systemic inflammatory disease that mainly affects diarthrodial joints. Its global prevalence is 0,5-1 % in adults, increasing to 5 % in women over 55 years old. RA reduces the quality of life and life expectancy by 3-10 years, mainly due to associated cardiovascular diseases. Current treatment is based on initiating early disease-modifying therapy with the goal of suppressing inflammation, inducing remission, preventing joint damage, and improving functionality. Antirheumatic medications include non-steroidal anti-inflammatory drugs, glucocorticoids, non-biological immunosuppressants like methotrexate, and biological immunomodulators such as anti-TNF or anti-interleukins, which have shown high clinical effectiveness. However, there is individual variability in therapeutic response, adverse effects, and loss of efficacy over time. This study conducted a systematic literature review following the PRISMA methodology. The search was performed on PubMed, Scopus, and Web of Science, using MESH terms and keywords related to rheumatoid arthritis, treatments, effectiveness, and prognostic factors. Studies published between 2015-2022 were included, ultimately selecting 30 articles that met eligibility criteria. The objective of this review was to compile and synthesize available evidence on currently used medications and therapies for rheumatoid arthritis, factors associated with therapeutic success, and the most frequently reported complications or adverse effects. The results contribute to enhancing treatment strategies, considering a personalized approach based on each patient's needs.
References
1. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA - J Am Med Assoc. 2018;320(13):1360–72. Disponible en: https://doi.org/10.1001/jama.2018.13103
2. Jafarzadeh SR, Felson DT. Updated Estimates Suggest a Much Higher Prevalence of Arthritis in United States Adults Than Previous Ones. Arthritis Rheumatol. 2018;70(2):185–92. Disponible en: https://doi.org/10.1002/art.40355
3. Almutairi KB, Nossent JC, Preen DB, Keen HI, Inderjeeth CA. The prevalence of rheumatoid arthritis: A systematic review of population-based studies. J Rheumatol. 2021;48(5):669–76. Disponible en: https://doi.org/10.3899/jrheum.200367
4. McInnes I, Schett G. The pathogenesis of rheumatoid arthritis. Immunity. 2022;55(12):2255–70. Disponible en: https://doi.org/10.1016/j.immuni.2022.11.009
5. Mariani FM, Martelli I, Pistone F, Chericoni E, Puxeddu I, Alunno A. Pathogenesis of rheumatoid arthritis: one year in review 2023. Clin Exp Rheumatol. 2023;41(9):1725–34. Disponible en: https://doi.org/10.55563/clinexprheumatol/sgjk6e
6. Avina J, Thomas J, Sadatsafavi M, Lehman A, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524–9. Disponible en: https://doi.org/10.1136/annrheumdis-2011-200726
7. Cassotta M, Pistollato F, Battino M. Rheumatoid arthritis research in the 21st century: Limitations of traditional models, new technologies, and opportunities for a human biology-based approach. ALTEX. 2020;37(2):223–42. Disponible en: https://doi.org/10.14573/altex.1910011
8. Ramirez M, Lara J, Torres J, Arana V. Capítulo 8 Inmunopatogénesis de la Artritis Reumatoide Diagnóstico y estrategias terapéuticas Víctor Ermilo Arana Argáez , Julio Cesar Torres Romero , [Internet]. 2016. 1–36 p. Disponible en: https://www.researchgate.net/publication/312605286_Inmunopatogenesis_de_la_Artritis_ReumatoideDiagnostico_y_estrategias_terapeuticas.
9. Viatte S, Barton A. Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. Semin Immunopathol. 2017;39(4):395–408. Disponible en: https://doi.org/10.1007/s00281-017-0630-4
10. Marcos T, Tarraga Marcos A, Juan Tárraga López REVISIÓN P, Jesús Davia Cantos M, Tarraga Marcos L, Juan Tárraga López P, et al. Patología Orgánica Asociada Al Tabaquismo Organic Pathology Associated With Smoking. 2022;10:385–408. Disponible en: https://doi.org/10.19230/jonnpr.4801
11. Smolen J, Landewé R, Bijlsma J, Burmester G, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):S685–99. Disponible en: https://doi.org/10.1136/annrheumdis-2019-216655
12. Smolen J, Landewé R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2022;82(1):3–18. Disponible en: https://doi.org/10.1136/ard-2022-223356
13. Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, et al. Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. N Engl J Med. 2014;371(19):1781–92. Disponible en: https://doi.org/10.1056/nejmoa1316133
14. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372. Disponible en: https://doi.org/10.1136/bmj.n16
15. Sarkis R, Catalá F, Aromataris E, Lockwood C. How to properly use the PRISMA Statement. Syst Rev [Internet]. 2021 Dec 19;10(1):117. Available from: https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-021-01671-z. Disponible en: https://doi.org/10.1186/s13643-021-01671-z
16. Hartmann A, Dell’oro M, Kessler C, Schumann D, Steckhan N, Jeitler M, et al. Efficacy of therapeutic fasting and plant-based diet in patients with rheumatoid arthritis (NutriFast): Study protocol for a randomised controlled clinical trial. BMJ Open. 2021;11(8):1–12. Disponible en: https://doi.org/10.1136/bmjopen-2020-047758
17. Singh J, Saag K, Bridges L, Akl E, Bannuru R, Sullivan M, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1–25. Disponible en: https://doi.org/10.1002/acr.22783
18. Agarwal N, Kamaraj A, McDonnell S, Khan W. Perioperative management of patients with rheumatoid arthritis undergoing orthopaedic surgery. J Perioper Pract. 2020;30(9):265–70. Disponible en: https://doi.org/10.1177/1750458919886186
19. Fleischmann R, Genovese M, Enejosa J, Mysler E, Bessette L, Peterfy C, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78(11):1454–62. Disponible en: https://doi.org/10.1136/annrheumdis-2019-215764
20. Taylor P, Keystone E, van der Heijde D, Weinblatt M, Morales L, Reyes J, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652–62. Disponible en: https://doi.org/10.1056/nejmoa1608345
21. Alten R, Mariette X, Lorenz H, Nüßlein H, Galeazzi M, Navarro F, et al. Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. Clin Rheumatol. 2019;38(5):1413–24. Disponible en: https://doi.org/10.1007/s10067-019-04449-w
22. Yu C, Jin S, Wang Y, Jiang N, Wu C, Wang Q, et al. Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. Clin Rheumatol. 2019;38(3):727–38. Disponible en: https://doi.org/10.1007/s10067-018-4340-7
23. Strand V, Lee E, Fleischmann R, Alten R, Koncz T, Zwillich S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis: Patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open. 2016;2(2):1–11. Disponible en: https://doi.org/10.1136/rmdopen-2016-000308
24. Mueller A, Payandeh Z, Mohammadkhani N, Mubarak S, Zakeri A, Bahrami A, et al. Recent advances in understanding the pathogenesis of rheumatoid arthritis: New treatment strategies. Cells. 2021;10(11):1–38. Disponible en: https://doi.org/10.3390/cells10113017
25. Souto A, Maneiro J, Gómez J. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: A systematic review and meta-analysis of drug registries and health care databases. Rheumatol (United Kingdom). 2016;55(3):523–34. Disponible en: https://doi.org/10.1093/rheumatology/kev374
26. Ozen G, Pedro S, England B, Mehta B, Wolfe F, Michaud K. Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease-Modifying Antirheumatic Drugs. ACR Open Rheumatol. 2019;1(7):424–32. Disponible en: https://doi.org/10.1002/acr2.11064
27. Kalb R, Fiorentino D, Lebwohl M, Toole J, Poulin Y, Cohen A, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: Results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatology. 2015;151(9):961–9. Disponible en: https://doi.org/10.1001/jamadermatol.2015.0718
28. Duong S, Crowson C, Athreya A, Atkinson E, Davis J, Warrington K, et al. Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data. Arthritis Res Ther [Internet]. 2022;24(1):1–11. Disponible en: https://doi.org/10.1186/s13075-022-02851-5.
29. Wang D, Yeo AL, Dendle C, Morton S, Morand E, Leech M. Severe infections remain common in a real-world rheumatoid arthritis cohort: A simple clinical model to predict infection risk. Eur J Rheumatol. 2021;8(3):133–8. Disponible en: https://doi.org/10.5152/eurjrheum.2020.20172
30. Kvarnström K, Westerholm A, Airaksinen M, Liira H. Factors contributing to medication adherence in patients with a chronic condition: A scoping review of qualitative research. Pharmaceutics. 2021;13(7):1–41. Disponible en: https://doi.org/10.3390/pharmaceutics13071100
31. Gul H, Harnden K, Saleem B. Defining the optimal strategies for achieving drug-free remission in rheumatoid arthritis: A narrative review. Healthc. 2021;9(12). Disponible en: https://doi.org/10.3390/healthcare9121726
32. Xie F, Chen L, Yun H, Levitan E, Curtis J. Benefits of methotrexate use on cardiovascular disease risk among rheumatoid arthritis patients initiating biologic disease-modifying antirheumatic drugs. J Rheumatol. 2021;48(6):804–12. Disponible en: https://doi.org/10.3899/jrheum.191326
33. Mulhearn B, Barton A, Viatte S. Using the immunophenotype to predict response to biologic drugs in rheumatoid arthritis. J Pers Med. 2019;9(4):1–15. Disponible en: https://doi.org/10.3390/cells10113017
34. Garner R, Ding T, Deighton C. Management of rheumatoid arthritis. Med (United Kingdom). 2021;42(5):237–42. Disponible en: https://doi.org/10.1016/j.mpmed.2014.02.004
35. Lopez C, Barbarroja N, Patiño A, Luque M, Collantes E, Escudero A, et al. Effects of biological therapies on molecular features of rheumatoid arthritis. Int J Mol Sci. 2020;21(23):1–30. Disponible en: https://doi.org/10.3390/ijms21239067
36. Lortholary O, Fernandez M, Baddley J, Manuel O, Mariette X, Winthrop K. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: A viewpoint in 2020. Ann Rheum Dis. 2020;79(12):1532–43. Disponible en: https://doi.org/10.1136/annrheumdis-2020-217092
37. Aureal M, Seauve M, Laplane S, Lega JC, Cabrera N, Coury F. Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: A systematic review and meta-analysis of randomised controlled trials, open-label studies and observatio. RMD Open. 2023;9(3):1–15. Disponible en: https://doi.org/10.1136/rmdopen-2023-003064
38. Nagy G, Roodenrijs N, Welsing P, Kedves M, Hamar A, Van der Goes M, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;81(1):20–33. Disponible en: https://doi.org/10.1136/annrheumdis-2021-220973
39. Akintayo R, Bahiri R, El Miedany Y, Olaosebikan H, Kalla AA, Adebajo A, et al. African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic. Clin Rheumatol. 2021;40(9):3445–54. Disponible en: https://doi.org/10.1007/s10067-020-05355-2
40. Taylor P, Matucci M, Alten R, Avouac J, Westhovens R. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. Ther Adv Musculoskelet Dis. 2022;14:1–14. Disponible en: https://doi.org/10.1177/1759720X221114101
41. Martinez L, Palterer B, Vitiello G, Parronchi P, Robinson W, Mahler M. Autoantibodies to protein-arginine deiminase (PAD) 4 in rheumatoid arthritis: immunological and clinical significance, and potential for precision medicine: Anti-PAD4 antibodies in RA. Expert Rev Clin Immunol. 2019;15(10):1073–87. Disponible en: https://doi.org/10.1080/1744666X.2020.1668778
42. Emery P, Tanaka Y, Bykerk V, Huizinga T, Citera G, Bingham C, et al. Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis. Rheumatol Ther [Internet]. 2023;10(3):707–27 Disponible en: https://doi.org/10.1007/s40744-022-00519-9
Published
Issue
Section
License
Copyright (c) 2024 Jonathan Rocha (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
